Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714947 · ClinicalTrials.gov registry record · Phase 1
Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib
A Phase 1 study of Lymphoma and Advanced Solid Tumors, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT01714947: Completed Phase 1 study of Lymphoma and Advanced Solid Tumors, sponsored by Millennium Pharmaceuticals.
NCT01714947 is a Phase 1 study of Lymphoma and Advanced Solid Tumors that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 3 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01714947, a Phase 1 study of Lymphoma and Advanced Solid Tumors, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the mass balance (i.e. cumulative excretion of total radioactivity \[TRA\] in urine and feces) of alisertib and pharmacokinetic (PK) of alisertib in plasma and urine, and of TRA in plasma and whole blood.
Conditions Studied
Interventions
- DRUG alisertib
- DRUG [^14C]-alisertib
Study Locations (1)
Washington
- Comprehensive Clinical Development - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-01-24 |
| Est. Completion | 2013-06-14 |
| Phase | Phase 1 |
What the finished NCT01714947 record still lists
NCT01714947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which alisertib is the first listed.
NCT01714947 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT01714947 about?
NCT01714947 is a clinical study titled "Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib". The purpose of this study is to assess the mass balance (i.e. cumulative excretion of total radioactivity \[TRA\] in urine and feces) of alisertib and pharmacokinetic (PK) of alisertib in plasma and urine, and of TRA in plasma and whole blood.
What is the current status of trial NCT01714947?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2013-01-24. Estimated completion is 2013-06-14.
What conditions does trial NCT01714947 study?
This clinical trial studies the following conditions: Lymphoma, Advanced Solid Tumors.
What interventions are being tested in trial NCT01714947?
The interventions under investigation include: alisertib (DRUG), [^14C]-alisertib (DRUG).
Who is sponsoring clinical trial NCT01714947?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01714947 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01714947's enrollment target sits among peer trials
3 293rd of 299 higher than 4 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI